Mr. Dennis, 41, is currently senior director of International Equities, Invesco AIM. As a global equity strategist, he has extensive experience analyzing business models, corporate strategies and market trends with a particular emphasis on the European pharmaceutical industry. He is involved in several different funds and mandates with a collective net asset value of approximately $11 billion, and is directly responsible for managing $6 billion of international and global equity assets.
About Savara, Inc.
Savara (www.savarapharma.com) is developing next generation pulmonary drug delivery solutions using its NanoCluster formulation technology, which is now available for evaluation and license. Medicines manufactured using the NanoCluster technology are formulated directly from nanoparticle actives without the need for carrier particles or spray drying. The aerodynamics of NanoCluster formulations are fully customizable and permit targeted deposition of medicines to specific lung regions, including the deep lung. Savara expects that these NanoCluster features will translate into numerous patient benefits including reduced doses, enhanced efficacy, improved safety and tolerability as well as greater patient convenience.
Contact Information Media: Ian Stone Russo Partners, LLC (619) 528-2220 Ian.Stone@russopartnersllc.com Partners: Josef Bossart (512) 535-3613 Jbossart@savarapharma.com
|SOURCE Savara, Inc.|
Copyright©2009 PR Newswire.
All rights reserved